Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP)
· seekingalpha.com
Helus Pharma buy thesis ahead of HLP003 Phase 3 APPROACH topline data (4Q26), cash runway/dilution risks, and 2028 NDA path. Click for more on HELP stock.
Since I first covered Helus Pharma ( HELP ), the stock has actually run up quite a bit. It's up about 44% year-to-date and a hefty 139% since my last coverage. ...